EU nod for new metastatic colorectal cancer combination
Pierre Fabre’s Braftovi in combination with Erbitux is the first licensed therapy for a specific subset of colorectal cancer patients
Read More
Tag: encorafenib
EU approves new option for metastatic melanoma
The European Commission (EC) has granted marketing authorisation for Pierre Fabre’s Braftovi and Mektovi combination therapy for the treatment of adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
Read More
FDA approves Pierre Fabre/Array Biotech melanoma combo
US regulators have issued a green light for Pierre Fabre and Array Biotech’s encorafenib/binimetinib combination therapy for advanced BRAF-mutant melanoma.
Read More
Pierre Fabre, Array showcase potential of triple therapy for CRC
Pierre Fabre and Array BioPharma have unveiled data from a late-stage trial showing a significant improvement in one-year survival in colorectal cancer patients taking encorafenib, binimetinib and cetuximab versus the standard of care.
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
